Drug
Iruplinalkib tablets
Iruplinalkib tablets is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_2
1
33%
Ph early_phase_1
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruiting
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
NCT07374614
not_yet_recruitingphase_2
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
NCT07330076
recruitingearly_phase_1
An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
NCT06436885
Clinical Trials (3)
Showing 3 of 3 trials
NCT07374614
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
NCT07330076Phase 2
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
NCT06436885Early Phase 1
An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3